WAT

Waters Corporation

$453.42

-1.48%
Nov 16, 2026
Bobby Quantitative Model
Waters Corporation is a life-sciences tools company that designs and manufactures liquid chromatography, mass spectrometry, and thermal analysis instruments, along with the consumables and service contracts that accompany them, serving pharmaceutical, clinical diagnostics, academic, and industrial end markets. Historically a high-margin analytical-instruments pure-play, Waters has been transformed into a broader diagnostics and discovery platform following its early-2026 merger with Becton Dickinson's life science and diagnostics business, materially increasing its exposure to clinical diagnostics and biopharma discovery workflows. The investor narrative is now dominated by post-merger integration: the deal roughly doubled the revenue base and diluted near-term margins and GAAP earnings, creating a debate over whether management can realize cost and revenue synergies fast enough to justify the premium multiple. With no dividend and a heavy debt load added to the balance sheet, the stock has become a show-me story where execution on integration, consumables attach rates, and a recovery in biopharma instrument spending are the key swing factors driving sentiment.

People also watch

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

Analysis
Danaher Corporation

Danaher Corporation

DHR

Analysis
Natera

Natera

NTRA

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis

BobbyInvestment Opinion: Should I buy WAT Today?

Rating: Hold (accumulate on weakness). The core thesis is that Waters' merger with BD's life-science and diagnostics business has created a larger, more diversified platform whose earnings power is temporarily obscured by purchase accounting and integration costs, and at $460.25 the stock already discounts much of the recovery — the $503.29 average target implies only +9.4% upside against a $387 low target that implies roughly -16% downside, an unattractive near-term risk/reward despite a 1.67 recommendation mean and 18 of 23 analysts at Buy. The quality of the franchise (57.77% gross margin, 28.22% operating margin, $291.6 million TTM free cash flow) argues for ownership; the 35.17x trailing PE argues for patience on entry.

Supporting evidence is genuinely mixed but leans constructive on operations and cautious on price. Revenue reached $1.767 billion in Q3 2026, up 120.91% year-over-year and roughly 7.4% sequentially from $1.645 billion, and net income swung to $81 million from losses of $72 million and $136 million in Q1 and Q2, with EBITDA margin at 24.17% and operating margin at 7.24%. The recurring base — service at $298.9 million and chemistry consumables at $170.4 million — plus TTM free cash flow of $291.6 million and a 1.73 current ratio show the business funds itself. But the valuation metrics are demanding: 35.17x trailing and 27.85x forward earnings, 8.94x EV/sales, 23.23x EV/EBITDA, 7.14x PS and a PEG of 75.6, against a GAAP gross margin of 50.25% versus 59.79% pre-merger and a net margin of 4.58% versus 24.16%. The +9.4% average target upside is thin relative to a 42%-wide target range.

Three risks could invalidate the thesis: gross margin stalling near 50% rather than recovering toward the high-50s, which would make the 27.85x forward multiple indefensible; continued working-capital strain, evidenced by Q3 operating cash flow of just $98 million after a $384 million outflow against $53 million of quarterly interest expense on debt-to-equity of 0.58; and a slow biopharma instrument-spending recovery that keeps organic growth (as distinct from the 120.91% consolidation-driven jump) unproven. This Hold would upgrade to Buy on evidence of gross margin above 55% with positive organic growth, or on a pullback toward the $430-440 consolidation zone that restores double-digit upside to the $503 average target; it would downgrade to Sell if gross margin fails to expand sequentially for two quarters or if analysts begin cutting toward the $387 low. Verdict: fairly valued to modestly overvalued relative to its own history and to diagnostics peers — the 35.2x trailing PE sits in the upper-middle of its historical 22-26x to 40x+ band, and the stock is priced for a successful integration rather than offering a discount to it.

Sign up to view all

WAT 12-Month Price Forecast

Waters is a high-quality analytical-instruments franchise mid-transformation, and the Q3 swing to $81 million of net income from two consecutive quarterly losses shows the combined entity can generate operating leverage. But the stock at $460.25 already reflects much of that recovery: only +9.4% upside to the average target, a 35.17x trailing multiple, and a PEG of 75.6 mean the market is paying today for margin restoration that has not yet appeared in GAAP results. The 37.67-point six-month relative-strength gap versus SPY and 18 Buy ratings confirm strong sentiment, yet the 42%-wide target range shows the Street itself is divided on the merger's outcome. I would upgrade to bullish on two consecutive quarters of gross-margin expansion above 55% combined with positive organic growth, or on a pullback toward the $430-440 support zone that restores meaningful upside to consensus; I would downgrade to bearish if gross margin stalls near 50% or if targets begin migrating toward the $387 low.

Historical Price
Current Price $453.42
Average Target $481.50
High Target $550.00
Low Target $387.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $503.29 and implied upside of +11.0% versus the current price.

Average Target

$503.29

24 analysts

Implied Upside

+11.0%

vs. current price

Analyst Count

24

covering this stock

Price Range

$387 - $550

Analyst target range

Buy
18 (75%)
Hold
5 (21%)
Sell
1 (4%)

Coverage is robust, with 23 analysts and a distribution of 18 Buy, 5 Hold, and 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.67 (where 1 is a strong buy). The average target price of $503.29 implies roughly +9.4% upside from the current $460.25, a moderate rather than aggressive bullish signal that suggests much of the recovery is already priced in. Recent institutional actions are uniformly constructive, with Citigroup, KeyBanc, RBC, TD Cowen, Barclays, Guggenheim, and Goldman Sachs all reiterating Buy/Overweight/Outperform ratings in October and November 2026, while JP Morgan remains Neutral. The target range of $387 to $550 is wide, spanning about 42% of the current price, which signals meaningful disagreement about the merger's outcome. The $550 high target likely assumes successful synergy capture, gross-margin recovery toward the high-50s, and a re-rating toward the upper end of the historical multiple band, while the $387 low target appears to price in integration missteps, persistent margin compression, and a slower biopharma capex recovery. The absence of recent downgrades and the clustering of reiterations around the November 4 earnings date suggest analysts are holding conviction pending evidence of margin recovery, and the wide spread means position sizing should reflect genuine execution uncertainty rather than consensus complacency.

Drowning in data?

Find the real signal!

Bulls vs Bears: WAT Investment Factors

The bull case rests on a genuinely transformed franchise: revenue more than doubled to $1.767 billion in Q3 2026, profitability swung back positive at $81 million, and the stock has outperformed SPY by 37.67 points over six months with 18 of 23 analysts at Buy. The bear case is equally concrete: a 35.17x trailing PE and 75.6 PEG price in a margin recovery that has not yet happened, GAAP gross margin sits at 50.25% versus 59.79% pre-merger, and the balance sheet is newly levered with debt-to-equity of 0.58. On balance the evidence currently favors the bulls, but narrowly — momentum, analyst conviction and the profit inflection outweigh valuation risk only because the market is willing to look through integration noise. The single most important tension is whether management can restore gross margins toward the high-50s; if that happens the forward multiple of 27.85x looks reasonable, but if margins stall near 50% the premium collapses and the $387 bear target comes into play.

Bullish

  • Merger doubles revenue base: Q3 2026 revenue hit $1.767 billion, up 120.91% year-over-year, versus $1.267 billion in Q1 2026, reflecting the step-change from the BD life-sciences consolidation. Sequential growth of roughly 7.4% from Q2 to Q3 shows the combined business is building momentum rather than stalling post-close.
  • Strong momentum and relative strength: The stock is up 39.80% over six months versus just 2.13% for SPY, a 37.67-point relative-strength gap, and sits at roughly 88.4% of its 52-week range ($282.77-$483.33). One-month relative strength of +7.67 points confirms the outperformance is persistent, not a single spike.
  • Analyst consensus firmly constructive: Of 23 analysts, 18 rate Buy, 5 Hold and only 1 Sell, producing a recommendation mean of 1.67 and an average target of $503.29, about +9.4% above the $460.25 price. Citigroup, KeyBanc, RBC, TD Cowen, Barclays, Guggenheim and Goldman all reiterated Buy/Overweight/Outperform in October-November 2026 with no recent downgrades.
  • Profitability inflecting off the trough: Q3 2026 swung back to $81 million of net income from losses of $72 million in Q1 and $136 million in Q2, with a 24.17% EBITDA margin and 7.24% operating margin. That operating leverage demonstrates the combined entity can convert revenue into profit as integration costs normalize.

Bearish

  • Valuation leaves no room for error: At 35.17x trailing and 27.85x forward earnings, plus 8.94x EV/sales and 23.23x EV/EBITDA, WAT trades at a premium to diagnostics and life-science tools peers. The PEG ratio of 75.6 signals near-term earnings growth is far too thin to justify the multiple on a growth-adjusted basis.
  • GAAP margins deeply compressed: Q3 gross margin of 50.25% is far below the pre-merger Q4 2025 level of 59.79%, and the 4.58% net margin compares with 24.16% before the deal. Purchase accounting, amortization and integration costs are masking the underlying earnings power, and restoring margins to the high-50s is unproven.
  • Leverage and working-capital strain: Debt-to-equity of 0.58 and interest expense of $53 million in Q3 alone weigh on the newly levered balance sheet. Q3 operating cash flow of just $98 million was dragged down by a $384 million working-capital outflow, and ROA of only 3.87% reveals the capital intensity of the enlarged asset base.
  • Organic growth still unproven: The 120.91% revenue jump is consolidation, not organic expansion; the pre-merger base implies only modest underlying growth dependent on a biopharma instrument-spending recovery. With no dividend and a 3.63 short ratio, the stock depends on continued execution to hold its re-rating.

WAT Technical Analysis

Waters is in a sustained, powerful uptrend: the stock is up 21.34% over the past year and 20.50% year-to-date, and at $460.25 it sits at roughly 88.4% of its 52-week range (low $282.77, high $483.33). That positioning near the top of the range signals strong momentum rather than deep value, though it also leaves limited headroom to the prior high and raises the risk of profit-taking. The 6-month gain of 39.80% versus a 2.13% rise in SPY underscores how decisively the market has re-rated the post-merger story. Recent momentum is accelerating but flattening at the highs: the 1-month change of +5.41% and 3-month change of +11.67% both lag the 6-month move, indicating the pace of advance is decelerating even as direction remains positive. Relative strength is uniformly strong, with 1-month relative strength of +7.67 points, 3-month +14.50, and 6-month +37.67 versus the S&P 500, confirming persistent outperformance. The stock's pullback from the $483.33 high to $460.25 (about -4.8%) looks like consolidation rather than reversal, but the decelerating short-term slope warrants watching for a momentum divergence. Key resistance sits at the 52-week high of $483.33, and a decisive breakout would confirm the uptrend's continuation and likely invite momentum buyers; support is anchored near the 52-week low of $282.77, with intermediate support likely around the $430-440 area where the stock consolidated in September and October. With a beta of 1.148, Waters is roughly 15% more volatile than the market, and its max drawdown of -31.32% over the period shows it can endure sharp corrections, so position sizing should account for above-market volatility despite the current orderly trend.

Beta

1.15

1.15x market volatility

Max Drawdown

-31.3%

Largest decline past year

52-Week Range

$283-$483

Price range past year

Annual Return

+19.5%

Cumulative gain past year

PeriodWAT ReturnS&P 500
1m+3.8%-3.0%
3m+13.0%-3.6%
6m+32.8%-0.2%
1y+19.5%+10.1%
ytd+18.7%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

WAT Fundamental Analysis

Revenue has been transformed by the BD life-sciences merger: the most recent quarter (ended October 3, 2026) posted revenue of $1.767 billion, up 120.91% year-over-year, versus $1.645 billion in the prior quarter and $1.267 billion in Q1 2026, reflecting the step-change from consolidation rather than organic growth. Sequential growth of roughly 7.4% from Q2 to Q3 suggests the combined business is building momentum, and segment data shows instrument systems ($354.7 million) and service ($298.9 million) as the largest Waters lines, with chemistry consumables at $170.4 million providing the recurring, high-margin base. The key question for the investment case is whether this is a one-time merger-driven jump or the start of a durable growth trajectory, and the modest organic growth implied by the pre-merger base suggests the latter still depends on biopharma spending recovery. Profitability is uneven and integration-distorted: Q3 net income was $81 million (net margin 4.58%) with a 50.25% gross margin, a sharp compression from the pre-merger Q4 2025 gross margin of 59.79% and net margin of 24.16%, while Q1 and Q2 2026 posted net losses of $72 million and $136 million respectively. The Q3 swing back to profit and a 24.17% EBITDA margin show the combined entity can generate operating leverage, but GAAP margins remain well below Waters' historical ~58-60% gross margin profile, reflecting purchase accounting, amortization, and integration costs. Management's ability to restore gross margins toward the high-50s is the central profitability test. Balance-sheet health is adequate but levered: debt-to-equity is 0.58, the current ratio is 1.73, and TTM free cash flow is $291.6 million, while Q3 operating cash flow of $98 million was dragged down by a $384 million working-capital outflow. ROE of 25.09% looks strong but is flattered by the merger's accounting, whereas ROA of just 3.87% reveals the capital intensity of the enlarged asset base. Cash of $593 million against meaningful debt and a 3.63 short ratio suggests the company can fund operations internally but has limited cushion for further large acquisitions without additional financing.

Quarterly Revenue

$1.8B

2026-10

Revenue YoY Growth

+120.9%

YoY Comparison

Gross Margin

50.2%

Latest Quarter

Free Cash Flow

$291580000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Chemistry Consumables
Ta Instrument Systems
Ta Service
Waters Instrument Systems
Waters Service

Open an Account, get $2 TSLA now!

Valuation Analysis: Is WAT Overvalued?

Because net income is positive on a trailing basis, the PE ratio is the primary metric: Waters trades at 35.17x trailing earnings versus 27.85x forward, a 21% compression that implies the market expects meaningful EPS growth as merger synergies and margin recovery materialize. The forward multiple is more reasonable but still rich for a tools company, and the PEG ratio of 75.6 signals that near-term earnings growth is far too thin to justify the multiple on a growth-adjusted basis. Against the broader medical diagnostics and life-science tools peer group, the 35.2x trailing PE and 7.14x PS represent a premium, consistent with Waters' historically high-quality franchise, though the 8.94x EV/sales and 23.23x EV/EBITDA are elevated relative to the company's own pre-merger norms. The premium is partly defensible given the recurring consumables and service mix and 57.77% gross margin, but the depressed 20.30% net margin and 28.22% operating margin mean the earnings base is still recovering, so the multiple is being paid on normalized rather than current profitability. Historically, Waters has traded in a wide PE band, from roughly 22-26x in 2021-2023 to over 40x in earlier growth phases; the current 35.2x trailing sits in the upper-middle of that range, while the 7.14x PS is well below the 20-30x PS levels seen in 2021-2022 when the share count and revenue base were far smaller. The stock is therefore not at a historical extreme on sales but is priced for a successful integration and margin recovery, leaving little room for disappointment.

PE

35.2x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 22x~36x

vs. Industry Avg

35.2x

Industry PE ~35.2x*

EV/EBITDA

23.2x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the merger's accounting and cash-flow distortion. Q3 2026 gross margin of 50.25% is roughly 9.5 points below the pre-merger Q4 2025 level of 59.79%, and the 4.58% net margin compares with 24.16%, with Q1 and Q2 posting losses of $72 million and $136 million respectively. Interest expense of $53 million per quarter on debt-to-equity of 0.58 consumes a meaningful share of operating income, while Q3 operating cash flow of only $98 million was hit by a $384 million working-capital outflow despite $291.6 million of TTM free cash flow. ROA of just 3.87% against a flattered 25.09% ROE shows the enlarged asset base is not yet earning its cost of capital, and revenue concentration in instrument systems ($354.7 million) leaves the top line exposed to a slow biopharma capex recovery.

Market and competitive risks are dominated by valuation compression. At 35.17x trailing and 27.85x forward earnings, 8.94x EV/sales and 23.23x EV/EBITDA, WAT carries a premium to diagnostics and life-science tools peers, and a PEG of 75.6 means any earnings disappointment is punished disproportionately. The beta of 1.148 makes the stock roughly 15% more volatile than the market, amplifying sector rotation out of high-multiple healthcare names, and the 42%-wide analyst target range ($387-$550) shows the Street itself disagrees on the outcome. With no dividend and a 3.63 short ratio, there is no income cushion and meaningful bearish positioning that could accelerate a selloff on negative integration news.

The worst-case scenario is a chain in which biopharma instrument spending stays soft, gross margins stall near 50% instead of recovering toward the high-50s, and integration costs persist into 2027 — forcing analysts to cut targets toward the $387 low. From the current $460.25, that implies roughly -16%, and a fuller de-rating toward the 52-week low of $282.77 would mean about -39%. The stock's -31.32% max drawdown over the period shows such a move is well within its historical behavior, so position sizing should assume a realistic downside of -16% to -39% if the margin-recovery thesis breaks.

FAQ

Ranked by severity, the first risk is margin execution: GAAP gross margin of 50.25% in Q3 2026 is roughly 9.5 points below the pre-merger 59.79%, and net margin of 4.58% compares with 24.16%, so failure to expand sequentially would undermine the 27.85x forward multiple directly. Second is valuation compression: at 35.17x trailing earnings, 8.94x EV/sales and a PEG of 75.6, any earnings miss is punished disproportionately, and the 1.148 beta amplifies sector rotation out of high-multiple healthcare names. Third is financial strain from the newly levered balance sheet — debt-to-equity of 0.58, $53 million of quarterly interest expense, and Q3 operating cash flow of only $98 million after a $384 million working-capital outflow, with ROA of just 3.87% showing the enlarged asset base is not yet earning its cost of capital. Fourth is company-specific uncertainty over organic growth: the 120.91% revenue jump is consolidation, the $354.7 million instrument-systems line depends on a biopharma capex recovery, and the $387-$550 analyst target range spanning about 42% of the price confirms the Street itself is divided.

The base case carries 55% probability with a $460-$503 range, assuming integration proceeds on plan, revenue holds near the $1.7 billion quarterly run rate, GAAP gross margin improves gradually but stays below the pre-merger 59.79%, and EPS tracks the $22.33 consensus — a modest single-digit to low-double-digit return toward the $503.29 average target. The bull case at 25% probability targets $503-$550, requiring gross margin above 55% and a biopharma instrument-spending recovery that re-rates the stock toward the $550 high target, roughly +9% to +20% from $460.25. The bear case at 20% probability targets $387-$430, where soft biopharma capex, margins stalling near 50% and persistent integration costs push analysts toward the $387 low, about -16% from the current price. The base case is most likely, and its key assumption is that gross margin improves without a dramatic step-change while no further large acquisitions disturb the 0.58 debt-to-equity ratio.

WAT screens as fairly valued to modestly overvalued. The primary metric is the 35.17x trailing PE, which compresses to 27.85x forward — a 21% step-down that assumes meaningful EPS growth toward the $22.33 consensus — but the PEG of 75.6 reveals that near-term growth is far too thin to justify either multiple on a growth-adjusted basis. On sales the stock trades at 7.14x PS and 8.94x EV/sales, and on EBITDA at 23.23x, all elevated versus Waters' own pre-merger norms and versus diagnostics peers, though well below the 20-30x PS levels of 2021-2022 when the revenue base was far smaller. Against its own history the 35.2x trailing PE sits in the upper-middle of a band that has ranged from roughly 22-26x in 2021-2023 to over 40x in earlier growth phases. The market is therefore paying for a successful integration and a return of gross margin toward the high-50s; if that materializes the forward multiple looks reasonable, but if margins stall near 50% the premium is unsupported and the $387 bear target becomes the reference point.

The risk/reward is balanced rather than compelling at $460.25. Upside to the $503.29 average analyst target is only about +9.4%, while the $387 low target implies roughly -16% and the 52-week low of $282.77 implies about -39%, so the asymmetry does not favor aggressive new buying at current levels. The quality case is real — 18 of 23 analysts rate Buy with a 1.67 recommendation mean, revenue reached $1.767 billion in Q3 2026, and net income swung to $81 million from losses of $72 million and $136 million in the prior two quarters. But the 35.17x trailing PE, 27.85x forward PE and 75.6 PEG mean the market already pays for the margin recovery, and GAAP gross margin of 50.25% versus 59.79% pre-merger shows that recovery is unproven. It is a reasonable buy for long-horizon investors who can tolerate a 1.148 beta and a -31.32% historical drawdown, particularly on a pullback toward the $430-440 consolidation zone; it is a poor entry for anyone seeking near-term upside or income, since the dividend yield is zero.

WAT is better suited to long-term holding than short-term trading. The company is mid-transformation rather than early-stage — revenue has already more than doubled to $1.767 billion quarterly through the BD life-sciences merger — but the earnings recovery is a multi-quarter process, with GAAP gross margin at 50.25% versus 59.79% pre-merger and integration costs expected to persist into 2027, so the thesis needs time to play out. Volatility argues against short-term positioning: a beta of 1.148, a -31.32% max drawdown, a 3.63 short ratio and a 42%-wide analyst target range mean headline-driven swings are likely, and the stock's -4.8% pullback from the $483.33 high shows how quickly momentum can stall. There is no dividend (0% yield, 0% payout) to compensate for waiting, so total return depends entirely on price appreciation. A minimum holding period of 18-24 months is appropriate, covering at least four to six quarterly reports through 2027 to observe gross-margin progression and synergy realization; shorter horizons should be treated as trading the $430-440 support and $483 resistance range rather than investing.